The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma

Journal of Neuro-Oncology

Volumn 116, Issue 2, 2014, Pages 251-259

  Yue, Qi ^a   Zhang, Xin ^a   Ye, Hong Xing ^a   Wang, Yin ^a   Du, Zun Guo ^a   Yao, Yu ^a   Mao, Ying ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Foxp3; Glioblastoma; Prognosis; Regulatory T cell; Tumor infiltrating lymphocyte

Indexed keywords

CD8 ANTIGEN; KI 67 ANTIGEN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PARAFFIN; PROTEIN P53; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CD8+ T LYMPHOCYTE; CELL DENSITY; CLINICAL FEATURE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME; T LYMPHOCYTE SUBPOPULATION; TUMOR ASSOCIATED LEUKOCYTE;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD8; BRAIN NEOPLASMS; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GLIOBLASTOMA; HUMANS; KI-67 ANTIGEN; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84893637671     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1314-0     Document Type: Article

References (34)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi: 10.1056/NEJMoa043330
2. Rahman M, Hoh B, Kohler N, Dunbar EM, Murad GJ (2012) The future of glioma treatment: stem cells, nanotechnology and personalized medicine. Future Oncol 8:1149-1156. doi: 10.2217/fon.12.111
3. Parney IF (2012) Basic concepts in glioma immunology. Adv Exp Med Biol 746:42-52. doi: 10.1007/978-1-4614-3146-6-4
4. Cao X (2010) Regulatory T cells and immune tolerance to tumors. Immunol Res 46:79-93. doi: 10.1007/s12026-009-8124-7
5. Nishikawa H, Sakaguchi S (2010) Regulatory T cells in tumor immunity. Int J Cancer 127:759-767. doi: 10.1002/ijc.25429
6. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC (2002) Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169:2756-2761
7. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F (2005) Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 65:2457-2464. doi: 10.1158/0008-5472.CAN-04-3232
8. Ichihara F, Kono K, Takahashi A, Kawaida H, Sugai H, Fujii H (2003) Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin Cancer Res 9:4404-4408
9. Lowther DE, Hafler DA (2012) Regulatory T cells in the central nervous system. Immunol Rev 248:156-169. doi: 10.1111/j.1600-065X.2012.01130.x
10. DeLeeuw RJ, Kost SE, Kakal JA, Nelson BH (2012) The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature. Clin Cancer Res 18:3022-3029. doi: 10.1158/1078-0432.CCR-11-3216
11. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiraoka N, Fuller GN (2008) Incidence and prognostic impact of Foxp3+ regulatory T cells in human gliomas. Clin Cancer Res 14:5166-5172. doi: 10.1158/1078-0432.CCR-08-0320
12. Jacobs JF, Idema AJ, Bol KF, Grotenhuis JA, de Vries IJ, Wesseling P, Adema GJ (2010) Prognostic significance and mechanism of Treg infiltration in human brain tumors. J Neuroimmunol 225:195-199. doi: 10.1016/j.jneuroim.2010.05. 020
13. Wang L, Zhang B, Xu X, Zhang S, Yan X, Kong F, Feng X, Wang J (2013) Clinical significance of FOXP3 expression in human gliomas. Clin Transl Oncol. doi: 10.1007/s12094-013-1037-x
14. Yao Y, Tao R, Wang XM, Wang Y, Mao Y, Zhou LF (2009) B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells. Neuro Oncol 11:757-766. doi: 10.1215/15228517-2009-014
15. Yao Y, Wang XM, Jin KL, Zhu JH, Wang Y, Xiong SD, Mao Y, Zhou LF (2008) B7-H4 is preferentially expressed in non-dividing brain tumor cells and in a subset of brain tumor stem-like cells. J Neurooncol 89:121-129. doi: 10.1007/s11060-008-9601-x
16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109. doi: 10.1007/s00401-007- 0243-4
17. West NR, Kost SE, Martin SD, Milne K, Deleeuw RJ, Nelson BH, Watson PH (2013) Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer 108:155-162. doi: 10.1038/bjc.2012.524
18. Lee YM, Lee JB (2013) Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma. J Int Med Res 41:825-834. doi: 10.1177/0300060513477312
19. Melguizo C, Prados J, Gonzalez B, Ortiz R, Concha A, Alvarez PJ, Madeddu R, Perazzoli G, Oliver JA, Lopez R, Rodriguez-Serrano F, Aranega A (2012) MGMT promoter methylation status and MGMT and CD133 immunohistochemical expression as prognostic markers in glioblastoma patients treated with temozolomide plus radiotherapy. J Transl Med 10:250. doi: 10.1186/1479-5876-10-250
20. Yoshida Y, Nakada M, Harada T, Tanaka S, Furuta T, Hayashi Y, Kita D, Uchiyama N, Hayashi Y, Hamada J (2010) The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J Neurooncol 98:41-47. doi: 10.1007/s11060-009-0064-5
21. Wiencke JK, Accomando WP, Zheng S, Patoka J, Dou X, Phillips JJ, Hsuang G, Christensen BC, Houseman EA, Koestler DC, Bracci P, Wiemels JL, Wrensch M, Nelson HH, Kelsey KT (2012) Epigenetic biomarkers of T-cells in human glioma. Epigenetics 7:1391-1402. doi: 10.4161/epi.22675
22. Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I, Li G, Liau LM, Prins RM (2012) Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One 7:e32614. doi: 10.1371/journal.pone.0032614
23. Yang I, Tihan T, Han SJ, Wrensch MR, Wiencke J, Sughrue ME, Parsa AT (2010) CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci 17:1381-1385. doi: 10.1016/j.jocn.2010.03. 031
24. Kim YH, Jung TY, Jung S, Jang WY, Moon KS, Kim IY, Lee MC, Lee JJ (2012) Tumour-infiltrating T-cell subpopulations in glioblastomas. Br J Neurosurg 26:21-27. doi: 10.3109/02688697.2011.584986
25. Liu FF, Lang RG, Zhao J, Zhang XM, Pringle GA, Fan Y, Yin D, Gu F, Yao Z, Fu L (2011) CD8(+) cytotoxic T cell and FOXP3(+) regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat 130:645-655. doi: 10.1007/s10549-011-1647-3
26. Shen ZB, Zhou S, Wang YN, Li RL, Zhong CP, Liang CM, Sun YH (2010) Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin Oncol 136:1585-1595. doi: 10.1007/s00432-010-0816-9
27. Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA (2012) Prognostic impact of Foxp3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas. PLoS One 7:e42274. doi: 10.1371/journal.pone. 0042274
28. Whiteside TL (2010) Immune responses to malignancies. J Allergy Clin Immunol 125:S272-S283. doi: 10.1016/j.jaci.2009.09.045
29. Mathai AM, Kapadia MJ, Alexander J, Kernochan LE, Swanson PE, Yeh MM (2012) Role of Foxp3-positive tumor-infiltrating lymphocytes in the histologic features and clinical outcomes of hepatocellular carcinoma. Am J Surg Pathol 36:980-986. doi: 10.1097/PAS.0b013e31824e9b7c
30. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102:18538-18543. doi: 10.1073/pnas.0509182102
31. Ogino S, Galon J, Fuchs CS, Dranoff G (2011) Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 8:711-719. doi: 10.1038/nrclinonc.2011.122
32. Frey DM, Droeser RA, Viehl CT, Zlobec I, Lugli A, Zingg U, Oertli D, Kettelhack C, Terracciano L, Tornillo L (2010) High frequency of tumor-infiltrating FOXP3(+) regulatory T cells predicts improved survival in mismatch repair-proficient colorectal cancer patients. Int J Cancer 126:2635-2643. doi: 10.1002/ijc.24989
33. Mougiakakos D, Johansson CC, Trocme E, All-Ericsson C, Economou MA, Larsson O, Seregard S, Kiessling R (2010) Intratumoral forkhead box P3-positive regulatory T cells predict poor survival in cyclooxygenase-2-positive uveal melanoma. Cancer 116:2224-2233. doi: 10.1002/cncr.24999
34. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Lee AH, Ellis IO, Green AR (2011) An evaluation of the clinical significance of FOXP3+ infiltrating cells in human breast cancer. Breast Cancer Res Treat 127:99-108. doi: 10.1007/s10549-010-0987-8